Michael Levit's Insider Trades & SAST Disclosures
Michael Levit's most recent trade in Herbalife Nutrition Ltd was a trade of 21,857 Common Stock done . Disclosure was reported to the exchange on May 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael Levit.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Herbalife Nutrition Ltd | Michael J. Levitt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2025 | 21,857 | 37,514 (0%) | 0% | 0 | Common Stock | |
| Charles Schwab Corp. | Brian Michael Levitt | Director | 28 May 2024 | 4,496 | 4,496 | - | - | Nonqualified Stock Option (right to buy) | ||
| Charles Schwab Corp. | Brian Michael Levitt | Director | 28 May 2024 | 1,809 | 7,279 (0%) | 0% | 0 | Common Stock | ||
| Charles Schwab Corp. | Brian Michael Levitt | Director | 22 May 2024 | 197 | 5,470 (0%) | 0% | 78.7 | 15,506 | Common Stock | |
| Charles Schwab Corp. | Brian Michael Levitt | Director | 17 May 2024 | 241 | 5,829 (0%) | 0% | 77.9 | 18,779 | Common Stock | |
| Charles Schwab Corp. | Brian Michael Levitt | Director | 17 May 2024 | 162 | 5,667 (0%) | 0% | 78.5 | 12,716 | Common Stock | |
| Herbalife Nutrition Ltd | Michael J. Levitt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2024 | 15,657 | 15,657 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 51,682 | 51,682 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 21,329 | 21,329 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 8,888 | 49,565 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 8,888 | 8,888 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 5,875 | 42,402 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 5,875 | 11,749 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 4,438 | 37,830 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 4,438 | 0 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.79 per share. | 11 Mar 2024 | 2,610 | 46,955 (0%) | 0% | 25.8 | 67,312 | Common Stock |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.42 per share. | 11 Mar 2024 | 1,725 | 40,677 (0%) | 0% | 25.4 | 43,850 | Common Stock |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.42 per share. | 11 Mar 2024 | 1,303 | 36,527 (0%) | 0% | 25.4 | 33,122 | Common Stock |
| Charles Schwab Corp. | Brian Michael Levitt | Director | 22 May 2023 | 5,464 | 5,464 | - | - | Nonqualified Stock Option (right to buy) | ||
| Charles Schwab Corp. | Brian Michael Levitt | Director | 22 May 2023 | 2,496 | 6,070 (0%) | 0% | 0 | Common Stock | ||
| Charles Schwab Corp. | Brian Michael Levitt | Director | 19 May 2023 | 162 | 3,574 (0%) | 0% | 51.7 | 8,370 | Common Stock | |
| Charles Schwab Corp. | Brian Michael Levitt | Director | 17 May 2023 | 121 | 3,736 (0%) | 0% | 51.1 | 6,185 | Common Stock | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 8,888 | 32,447 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 8,888 | 17,776 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.10 per share. | 10 Mar 2023 | 2,609 | 29,838 (0%) | 0% | 26.1 | 68,095 | Common Stock |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 38,475 | 38,475 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 17,624 | 17,624 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 4,439 | 24,862 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 4,439 | 4,438 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.91 per share. | 09 Mar 2023 | 1,303 | 23,559 (0%) | 0% | 26.9 | 35,064 | Common Stock |
| Charles Schwab Corp. | Brian Michael Levitt | Director | 24 Oct 2022 | 37 | 3,857 (0%) | 0% | 70.4 | 2,605 | Common Stock | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2022 | 3,859 | 3,859 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2022 | 3,859 | 20,423 (0%) | 0% | 0 | Common Stock | |
| Charles Schwab Corp. | Brian Michael Levitt | Director | 19 May 2022 | 4,703 | 4,703 | - | - | Nonqualified Stock Option (right to buy) | ||
| Charles Schwab Corp. | Brian Michael Levitt | Director | 19 May 2022 | 2,054 | 3,894 (0%) | 0% | 0 | Common Stock | ||
| Charles Schwab Corp. | Brian Michael Levitt | Director | 17 May 2022 | 121 | 1,840 (0%) | 0% | 65.3 | 7,902 | Common Stock | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 38,979 | 38,979 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 26,664 | 26,664 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Purchase of securities on an exchange or from another person at price $ 24.62 per share. | 11 Mar 2022 | 4,000 | 15,924 (0%) | 0% | 24.6 | 98,476 | Common Stock |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2022 | 4,438 | 11,924 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 4,438 | 8,877 | - | - | Restricted Stock Unit | |
| Charles Schwab Corp. | Brian Michael Levitt | Director | 22 Oct 2021 | 37 | 1,961 (0%) | 0% | 83 | 3,071 | Common Stock | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Purchase of securities on an exchange or from another person at price $ 40.21 per share. | 11 Aug 2021 | 2,850 | 6,709 (0%) | 0% | 40.2 | 114,587 | Common Stock |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Purchase of securities on an exchange or from another person at price $ 40.20 per share. | 11 Aug 2021 | 777 | 7,486 (0%) | 0% | 40.2 | 31,239 | Common Stock |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 3,859 | 3,859 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 3,859 | 7,718 | - | - | Restricted Stock Unit | |
| Charles Schwab Corp. | Brian Michael Levitt | Director | 17 May 2021 | 4,390 | 4,390 | - | - | Nonqualified Stock Option (right to buy) | ||
| Charles Schwab Corp. | Brian Michael Levitt | Director | 17 May 2021 | 1,529 | 1,998 (0%) | 0% | 0 | Common Stock | ||
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2021 | 33,363 | 33,363 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2021 | 13,315 | 13,315 | - | - | Restricted Stock Unit | |
| Charles Schwab Corp. | Brian Michael Levitt | Director | 22 Oct 2020 | 1,243 | 1,243 | - | - | Nonqualified Stock Option (right to buy) | ||
| Charles Schwab Corp. | Brian Michael Levitt | Director | 22 Oct 2020 | 469 | 469 (0%) | 0% | 0 | Common Stock | ||
| Charles Schwab Corp. | Brian Michael Levitt | Director | 06 Oct 2020 | 21,846 | 21,846 (0%) | 0% | 0 | Common Stock | ||
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2020 | 57,145 | 57,145 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | Michael L. Levitz | EVP, CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2020 | 11,577 | 11,577 | - | - | Restricted Stock Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges